CN101173893A - Method for measuring drug-loading rate of bacteria nano magnetosomes - Google Patents
Method for measuring drug-loading rate of bacteria nano magnetosomes Download PDFInfo
- Publication number
- CN101173893A CN101173893A CNA200710190285XA CN200710190285A CN101173893A CN 101173893 A CN101173893 A CN 101173893A CN A200710190285X A CNA200710190285X A CN A200710190285XA CN 200710190285 A CN200710190285 A CN 200710190285A CN 101173893 A CN101173893 A CN 101173893A
- Authority
- CN
- China
- Prior art keywords
- solution
- reaction
- drug
- magnetosome
- bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002244 magnetosome Anatomy 0.000 title claims abstract description 53
- 241000894006 Bacteria Species 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims description 8
- 239000003814 drug Substances 0.000 claims abstract description 52
- 238000006243 chemical reaction Methods 0.000 claims abstract description 49
- 229940079593 drug Drugs 0.000 claims abstract description 26
- 239000006228 supernatant Substances 0.000 claims abstract description 14
- 238000002189 fluorescence spectrum Methods 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims description 37
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 35
- 230000000052 comparative effect Effects 0.000 claims description 16
- 239000012086 standard solution Substances 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000007853 buffer solution Substances 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 238000001228 spectrum Methods 0.000 claims description 3
- 238000002835 absorbance Methods 0.000 abstract description 7
- 238000002211 ultraviolet spectrum Methods 0.000 abstract description 5
- 230000005540 biological transmission Effects 0.000 abstract 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 44
- 230000002494 anti-cea effect Effects 0.000 description 22
- 229940009456 adriamycin Drugs 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000006249 magnetic particle Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- 238000005034 decoration Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229960000587 glutaral Drugs 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 239000002122 magnetic nanoparticle Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100123117 Nicotiana plumbaginifolia MSR-1 gene Proteins 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000005381 magnetic domain Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007811 spectroscopic assay Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Abstract
The invention relates to a way of determining the drug loading of the bacteria nanometer magnetosome, which uses an ultraviolet spectrum or a fluorescence spectrum to determine the biggest ultraviolet absorbing wavelength or biggest emission wavelength Gamma max of the tested drug. The ultraviolet absorbance values or the fluorescence transmission intensity values of the drug solution with different concentrations are tested at the Gamma max to draw the standard working curves. The drug with known concentration mixed-react with the bacteria nanometer magnetosome, and the magnetosome after reaction is separated to acquire the supernatant; and the drug solution with the same concentration and quantity with the former solution is prepared without reacting with the bacteria nanometer magnetosome to be as the comparison solution of the blank reaction; the ultraviolet absorbance value or the fluorescence transmission intensity value of the supernatant and the comparison solution of the blank reaction at the Gamma max are respectively determined, and the drug loading of the bacteria nanometer magnetosome is calculated by the standard working curves according to the difference of the two.
Description
Technical field
The present invention relates to a kind of assay method of drug-loading rate of bacteria nano magnetosomes, particularly relate to a kind of method that adopts ultraviolet spectrum or fluorescence spectrum indirect determination drug-loading rate of bacteria nano magnetosomes.
Background technology
Magnetictaxis bacteria (magnetotactic bacterium) is the peculiar microorganism of a class of U.S. biologist Bu Lake More (Blakemore) in 1975 nature existence serendipitous, it can move along the magnetic line of force, its cell contains the bacillus nanometer magnetosome (magnetosomes) that magnetic field is had susceptibility, it has played guiding in cell, and can move by means of the flagellum of self.The bacillus nanometer magnetosome size is about 35-120nm, and within the brilliant range of size of permanent single magnetic domain, principal ingredient is Fe
3O
4Or Fe
3S
4, there is the phosphatide lipid bilayer bag quilt by chimeric protein the outside, after the separation and purification in solution good dispersion, stability is high.Japan scholar Matsunaga will be a kind of new living resources during new and high technology is used in just estimating magnetotactic bacteria magnetic corpusculum 10 years in future in 1991.At fixed enzyme vector, immune detection, transgenosis, the result of study of aspects such as the separation of DNA, RNA and mark shows, the performance of bacillus nanometer magnetosome is better than the synthetic magnetic nanoparticle, the former immobilised enzymes amount big (but intelligent worker's synthesizing magnetic nano particle 100 times), antibody connection amount is big, the sensitivity of immune detection height, the DNA adsorbance is big, and application prospect is boundless.Compare with the synthetic magnetic nanoparticle, bacillus nanometer magnetosome is owing to from live bacteria, have superior Bc, and toxic and side effect is little; Its size is all at nanoscale, uniform particles, and stable crystal form has bigger specific surface area; The big and scalable of electronegativity is difficult for assembling; Because adipose membrane bag quilt is arranged, reactive group is abundant simultaneously, and various chemical modifications can be carried out in the surface, may become a kind of better nano-medicament carrier, are showing tempting application prospect aspect the target locating therapy tumour.Existing Primary Study result shows, the bacillus nanometer magnetosome epigranular, and change of size is little before and after its carrying medicament adriamycin, than the little 1-20 of medicine carrying magnetic particle of traditional synthetic doubly.Adopt biological nano magnetic corpusculum as pharmaceutical carrier, the exceeding more than 10 times of the comparable traditional synthetic magnetic particle of drug loading.
But because it is just at the early-stage to adopt bacillus nanometer magnetosome to carry out the research work of medicine carrying aspect, the method for mensuration drug-loading rate of bacteria nano magnetosomes does not have ready-made experience yet and can follow.Bibliographical information is arranged, and the drug loading for measuring synthetic nanometer magnetic particle adopts strong acid and intensive polar solvent that it is dissolved usually, measures after the extraction again.But for the bacillus nanometer magnetosome system, these strong acid and intensive polar solvent also very easily make the character of contained medicine change and decompose in dissolved destruction bacillus nanometer magnetosome film and magnetic nuclear, thereby influence the accurate mensuration of its drug loading.Therefore, how not destroying under character of medicine own and the active condition, accurately measuring the drug loading of bacillus nanometer magnetosome to medicine, is technical barrier anxious to be solved in the research work of present bacillus nanometer magnetosome medicine carrying.
Summary of the invention
The object of the present invention is to provide a kind of assay method of drug-loading rate of bacteria nano magnetosomes.Specifically, provide a kind of method that adopts ultraviolet spectrum or fluorescence spectrum indirect determination drug-loading rate of bacteria nano magnetosomes.The said bacillus nanometer magnetosome of the present invention is the nano magnetic particle that forms in the magnetotactic bacteria cell, particle diameter 35-120nm, and principal ingredient is Fe
3O
4Or Fe
3S
4, single magnetic particle has adipose membrane bag quilt.The medicine that this method relates to be can be coupled with bacillus nanometer magnetosome medicine.
The assay method of drug-loading rate of bacteria nano magnetosomes of the present invention comprises the steps:
(1) water or buffer solution are added in the medicine to be measured, make the pharmaceutical standards solution of a series of variable concentrations;
(2) be reference with pure water or corresponding buffer solution, measure said medicine standard solution ultraviolet scanning spectrum or fluorescence emission spectrum (wavelength coverage 190-900nm), determine uv-absorption maximum wavelength or maximum emission wavelength λ
MaxThe drug solution of measuring above-mentioned a series of known accurate concentration is at this λ
MaxThe ultraviolet absorptivity value or the fluorescent emission intensity value at place are made its standard working curve;
(3) drug solution with known accurate concentration mixes with bacillus nanometer magnetosome, makes them quantitatively decide volumetric reaction, and reaction is drawn to container bottom with the magnetic corpusculum in the reaction vessel with magnet after finishing outside reaction vessel, collect supernatant, and is to be measured; Again preparation a identical with above-mentioned mixed solution concentration not with the drug solution of bacillus nanometer magnetosome reaction as reacting blank comparative solution, stand-by;
(4) treat that measured reaction supernatant and the blank comparative solution of reaction are at λ in the determination step 3 respectively
MaxThe ultraviolet absorptivity value or the fluorescent emission intensity value at place;
(5) according to treating that measured reaction supernatant and the blank comparative solution of reaction are at λ
MaxThe ultraviolet absorptivity value at place or the difference of fluorescent emission intensity value by the respective standard working curve of contained medicine, calculate the drug loading of bacillus nanometer magnetosome.
Adopt the assay method of the drug-loading rate of bacteria nano magnetosomes of the invention described above, traditional ultraviolet spectrum or fluorescence spectrum are combined with the actual conditions of bacillus nanometer magnetosome medicine carrying reaction, variation indirect determination drug-loading rate of bacteria nano magnetosomes by reactant liquor Chinese traditional medicine concentration before and after the reaction, can under the condition of not destroying character of medicine own and activity, measure the drug loading of bacillus nanometer magnetosome to medicine.This method is simple to operate, and reliable results, and can guarantee the continuation of pharmaceutically active and reaction is for the mensuration of drug-loading rate of bacteria nano magnetosomes provides novel, reliable detection technological means.
Description of drawings
Fig. 1 is an adriamycin standard solution ultraviolet spectrogram.
Fig. 2 is the standard working curve (λ of adriamycin aqueous solution
Max=480nm).
Fig. 3 is anti-CEA standard solution fluorescence emission spectrogram.
Fig. 4 is the standard working curve of anti-CEA phosphate buffer solution.
Embodiment
Below the reagent and the instrument that adopt among each embodiment be described as follows:
Bacillus nanometer magnetosome (BMP): got by MSR-1 magnetotactic bacteria strain culturing, particle diameter is 40-50nm, is provided by Biology College, Chinese Agriculture Univ.'s department of microbiology.
Monoclonal anti CEA: available from SIGMA company.
Anticancer chemotherapeutic agent adriamycin (ADM): purchase in Pharmaceutical Technology Co., Ltd of Beijing Yun Di Tontru.
Water: secondary deionized water.It is pure that solvent for use and chemical reagent are analysis.
Instrument: day island proper Tianjin UV-3100 type ultraviolet-visible spectrometer, the thick 1cm of quartz cell; KQ-100 type ultrasonic oscillator; Perkin Elmer LS50B type fluorescence spectrophotometer, the thick 1cm of quartz cell.
Embodiment 1: adopt ultraviolet spectroscopy to measure the drug loading of the contained anticancer drugs, doxorubicin of bacillus nanometer magnetosome (BMP) (ADM).
(1) standard solution of preparation adriamycin: accurately take by weighing the 0.02g adriamycin, be dissolved in pure water, its standard solution of preparation in the 25ml volumetric flask.The above-mentioned adriamycin standard solution that pipettes different volumes is in the 25ml volumetric flask, and thin up accurately makes the adriamycin standard solution of a series of concentration known to scale.
(2) set up the standard working curve of contained medicine: do reference with pure water, measure above-mentioned adriamycin standard solution ultraviolet scanning spectrum, obtain its ultraviolet spectrum as shown in Figure 1.Can determine adriamycin maximum absorption wavelength λ in pure water solution according to Fig. 1
MaxBe 480nm.Measure the absorbance of the adriamycin solution of above-mentioned a series of known accurate concentration, make its standard working curve as shown in Figure 2 at the 480nm place.Determine that its equation of linear regression is A=23.73*C.A is an absorbance, and C is the adriamycin concentration of standard solution, and the ie in solution absorbance is directly proportional with the content of adriamycin in the solution.
(3) with medicine and bacillus nanometer magnetosome quantitative reaction: the bacillus nanometer magnetosome that pentanedial decoration is crossed mixes with the adriamycin solution of known accurate concentration, make that the bacillus nanometer magnetosome reaction density is 0.02mg/ml in the mixed liquor, the concentration of adriamycin is 0.2mg/ml, open ultrasonic oscillator, the two reaction, reaction is drawn to reaction container bottom with magnet with the magnetic corpusculum after finishing, collect supernatant, to be measured.
(4) the blank comparative solution of reaction of preparation adriamycin: a mixed solution with step (3) of preparation is the adriamycin medicine solution of 0.2mg/ml with the concentration of volume, as not with the blank comparative solution of the adriamycin of bacillus nanometer magnetosome reaction.
(5) ultraviolet spectroscopy: measure the ultraviolet absorptivity value of the blank comparative solution of reaction of supernatant and step (4) after the reaction of above-mentioned steps (3) gained respectively at the 480nm place.Recording the two difference in the ultraviolet absorptivity value at 480nm place is 0.254.
(6) calculating of drug loading: according to treating measured reaction supernatant (3) and the blank comparative solution of reaction (4) difference in the ultraviolet absorptivity value at 480nm place, by the determined equation of linear regression of respective standard working curve (Fig. 2) of contained medicine, the drug loading that calculates bacillus nanometer magnetosome is 536 μ gADM/mgBMP.
It should be noted that, no matter be to adopt ultraviolet spectroscopy or fluorescent spectrometry, all should prepare the blank comparative solution of reaction of adriamycin when carrying out medicine and bacillus nanometer magnetosome quantitative reaction simultaneously at every turn, fully consistent with the preparation condition that guarantees the blank comparative solution of reaction with reactant liquor, reduce experimental error.
Embodiment 2: adopt fluorescent spectrometry bacterial detection nanometer magnetic corpusculum to carry the anti-CEA content of monoclonal antibody.
(1) the anti-CEA standard solution of preparation: add phosphoric acid buffer solution, prepare the anti-CEA standard solution of a series of known accurate concentration.
(2) set up the standard working curve of anti-CEA: measure above-mentioned anti-CEA standard solution fluorescence emission spectrum, obtain its fluorescence emission spectrum as shown in Figure 3.Determine its maximum emission wavelength λ
MaxBe 336nm.Measure the fluorescent emission intensity value of the anti-CEA solution of above-mentioned a series of known accurate concentration, make its standard working curve as shown in Figure 4 at the 336nm place.Determine that its regression equation is I=8.047*10
3*C.The worker is an absorbance, and C is anti-CEA concentration of standard solution, and the ie in solution absorbance is directly proportional with the content of anti-CEA in the solution.
(3) will resist CEA and bacillus nanometer magnetosome quantitative reaction: the bacillus nanometer magnetosome that pentanedial decoration is crossed mixes with the anti-solution of the CEA of known accurate concentration, make that the bacillus nanometer magnetosome reaction density is 0.02mg/ml in the mixed liquor, the concentration of anti-CEA is 0.14mg/ml, open ultrasonic oscillator, the two reaction, reaction is drawn to reaction container bottom with magnet with the magnetic corpusculum after finishing, collect supernatant, to be measured.
(4) the blank comparative solution of reaction of the anti-CEA of preparation: a mixed solution with step (3) of preparation is the anti-CEA drug solution of 0.14mg/ml with the concentration of volume, as not with the blank comparative solution of the anti-CEA of bacillus nanometer magnetosome reaction.
(5) spectroscopic assay: the blank comparative solution of reaction that difference determination step (3) gained reaction supernatant and step (4) are prepared is in the fluorescent emission intensity value at 336nm place, and recording the two difference in the fluorescent emission intensity at 336nm place is 724.
(6) calculating of drug loading: according to treating measured reaction supernatant (3) and the blank comparative solution of reaction (4) difference in the fluorescent emission intensity value at 336nm place, respective standard working curve by contained medicine) determined equation of linear regression, the amount that calculates the anti-CEA of connection of bacillus nanometer magnetosome are the anti-CEA/mgBMP of 4.5mg.
Embodiment 3: the precision experiment
With the fluorescent spectrometry is example, as stated above same batch anti-CEA solution and pentanedial decoration bacillus nanometer magnetosome carried out parallel laboratory test simultaneously with same operating conditions, fluorescent emission intensity value according to each experiment, calculate the amount of the anti-CEA of connection of bacillus nanometer magnetosome, the result is as shown in table 1 below.This result shows that detection method of the present invention can reach desirable precision requirement.
Table 1 precision experimental result
| Experiment time numbering | 1 | 2 | 3 | 4 | 5 | 6 |
| Carry anti-CEA amount (the anti-CEA/mg BMP of mg) | 4.61 | 4.50 | 4.71 | 4.56 | 4.50 | 4.51 |
| Drug loading mean value (the anti-CEA/mg BMP of mg) | 4.57 | |||||
| RSD(％) | 1.8 | |||||
Table 1 shows, through six parallel testings, records the drug loading error with a collection of raw material in allowed band.
Claims (1)
1. method of measuring drug-loading rate of bacteria nano magnetosomes is characterized in that comprising following step:
(1) water or buffer solution are added in the medicine to be measured, make the pharmaceutical standards solution of a series of variable concentrations;
(2) be reference with pure water or corresponding buffer solution, measure said medicine standard solution ultraviolet scanning spectrum or fluorescence emission spectrum (wavelength coverage 190-900nm), determine uv-absorption maximum wavelength or maximum emission wavelength λ
MaxThe drug solution of measuring above-mentioned a series of known accurate concentration is at this λ
MaxThe ultraviolet absorptivity value or the fluorescent emission intensity value at place are made its standard working curve;
(3) drug solution with known accurate concentration mixes with bacillus nanometer magnetosome, makes them quantitatively decide volumetric reaction, and reaction is drawn to container bottom with the magnetic corpusculum in the reaction vessel with magnet after finishing outside reaction vessel, collect supernatant, and is to be measured; Again preparation a identical with above-mentioned mixed solution concentration not with the drug solution of bacillus nanometer magnetosome reaction as reacting blank comparative solution, stand-by;
(4) treat that measured reaction supernatant and the blank comparative solution of reaction are at λ in the determination step 3 respectively
MaxThe ultraviolet absorptivity value or the fluorescent emission intensity value at place;
(5) according to treating that measured reaction supernatant and the blank comparative solution of reaction are at λ
MaxThe ultraviolet absorptivity value at place or the difference of fluorescent emission intensity value by the respective standard working curve of contained medicine, calculate the drug loading of bacillus nanometer magnetosome.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200710190285XA CN100570333C (en) | 2007-11-26 | 2007-11-26 | A kind of method of measuring drug-loading rate of bacteria nano magnetosomes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200710190285XA CN100570333C (en) | 2007-11-26 | 2007-11-26 | A kind of method of measuring drug-loading rate of bacteria nano magnetosomes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101173893A true CN101173893A (en) | 2008-05-07 |
| CN100570333C CN100570333C (en) | 2009-12-16 |
Family
ID=39422533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200710190285XA Active CN100570333C (en) | 2007-11-26 | 2007-11-26 | A kind of method of measuring drug-loading rate of bacteria nano magnetosomes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100570333C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101666032B (en) * | 2009-08-24 | 2010-12-01 | 中华人民共和国苏州出入境检验检疫局 | Quantitative detection method of nanometer metal oxide substrate (MOX) on textile |
| CN103776808A (en) * | 2014-01-24 | 2014-05-07 | 鼎泰（湖北）生化科技设备制造有限公司 | Method for detecting hydroxyl radical concentration |
| CN104048739A (en) * | 2013-03-14 | 2014-09-17 | 飞旸生医有限公司 | Medicament dosage monitoring method and medicament dosage monitoring device |
| CN113777297A (en) * | 2021-08-14 | 2021-12-10 | 浙江大学 | Fluorescence differential rapid detection method based on magnetic nanoparticles |
-
2007
- 2007-11-26 CN CNB200710190285XA patent/CN100570333C/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101666032B (en) * | 2009-08-24 | 2010-12-01 | 中华人民共和国苏州出入境检验检疫局 | Quantitative detection method of nanometer metal oxide substrate (MOX) on textile |
| CN104048739A (en) * | 2013-03-14 | 2014-09-17 | 飞旸生医有限公司 | Medicament dosage monitoring method and medicament dosage monitoring device |
| CN103776808A (en) * | 2014-01-24 | 2014-05-07 | 鼎泰（湖北）生化科技设备制造有限公司 | Method for detecting hydroxyl radical concentration |
| CN113777297A (en) * | 2021-08-14 | 2021-12-10 | 浙江大学 | Fluorescence differential rapid detection method based on magnetic nanoparticles |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100570333C (en) | 2009-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Metal-organic framework as a multi-component sensor for detection of Fe3+, ascorbic acid and acid phosphatase | |
| Lin et al. | Simultaneous determination of quercetin and rutin at a multi-wall carbon-nanotube paste electrodes by reversing differential pulse voltammetry | |
| Rutter et al. | Quantification by SIFT-MS of acetaldehyde released by lung cells in a 3D model | |
| Shalali et al. | A sensitive electrochemical sensor amplified with ionic liquid and N-CQD/Fe3O4 nanoparticles for detection of raloxifene in the presence of tamoxifen as two essentials anticancer drugs | |
| CN100570333C (en) | A kind of method of measuring drug-loading rate of bacteria nano magnetosomes | |
| CN103961712A (en) | Superparamagnetic ferroferric oxide nano particle drug carrier, preparation method and application thereof | |
| CN104655759A (en) | Method for detecting recovery rate of [2,2-bis(4-hydroxyphenol)propane] absorbed by using aptamer functional magnetic nanomaterial | |
| CN108318438A (en) | The detection method of Ag doping fluorescent carbon quantum dot, preparation method and cholesterol | |
| CN111135308A (en) | Preparation method and application of polydopamine-coated mesoporous silica/elemene composite nanoparticle preparation | |
| CN110330974A (en) | A kind of preparation and application of zearalenone ratio fluorescent probe | |
| Cheng et al. | A Self‐Assembled ATP Probe for Melanoma Cell Imaging | |
| CN113549449A (en) | Nano fluorescent probe, preparation method and application thereof | |
| Wang et al. | Silver nanoparticles enhanced fluorescence for sensitive determination of fluoroquinolones in water solutions | |
| CN109128144A (en) | To the preparation method of the copper nanocluster of the wide response range of hydrogen peroxide | |
| Wang et al. | Rapid detection of malachite green in fish and water based on the peroxidase-like activity of Fe3O4NPs enhanced with aptamer | |
| CN104132936B (en) | A kind of stabilization, new peroxidase determination nitrite ion | |
| CN105503768B (en) | The preparation method of the fluorescence of alpha ketoglutaric acids/ultraviolet molecular probe and its application in biological specimen | |
| Liu et al. | Ultrasensitive molecularly imprinted electrochemiluminescence sensor based on enzyme-encapsulated liposome-linked signal amplification for trace analysis | |
| Wang et al. | A sensing platform for on-site detection of glutathione S-transferase using oxidized Pi@ Ce-doped Zr-based metal-organic frameworks (MOFs) | |
| CN101551382A (en) | Cell viability detection kit and preparation method and application thereof | |
| Zhang et al. | Flow injection spectrophotometric determination total antioxidant capacity in human serum samples based on response surface methodology to optimize synthesized peroxidase-like activity carbon dots | |
| AlRabiah et al. | Cyclodextrin potentiometric sensors based on selective recognition sites for procainamide: Comparative and theoretical study | |
| CN106645129A (en) | Method for detecting chlorpyrifos through functionalized gold nanoparticle based novel colorimetric sensor | |
| He et al. | Fluorescent aptamer-modified mesoporous silica nanoparticles for quantitative acetamiprid detection | |
| Ibrahim et al. | Development of a validated spectrofluorimetric method for assay of sotalol hydrochloride in tablets and human plasma: application for stability-indicating studies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160420 Address after: 210000 No. 213, Guangzhou Road, Gulou District, Jiangsu, Nanjing Patentee after: Nanjing Rui Rui Jie Biochemical Technology Co., Ltd. Address before: 210093 Hankou Road, Jiangsu, China, No. 22, No. Patentee before: Nanjing University |